UCC spin-out NeuroBell secures €4.8M to support US expansion

30 Jun 2026

University College Cork (UCC) spin-out NeuroBell has secured $5.5 million (€4.8 million) in funding to accelerate the launch of its AI-powered neonatal brain monitor, LUNA, as the company prepares to enter the US market.

The investment round was led by Elkstone, with participation from US health system Parkview Health. Existing investors Furthr VC, Atlantic Bridge, MedTech Syndicate and Enterprise Ireland also participated in the round.

Founded by Dr Mark O'Sullivan, Dr Alison O'Shea and Colm Murphy, NeuroBell spun out from UCC following years of research through the Irish Centre for Maternal and Child Health Research (INFANT). The company is developing technology to improve the detection of seizures in newborn babies receiving care in neonatal intensive care units (NICUs).

LUNA is a pocket-sized, wireless brain monitor that combines electroencephalography (EEG) with artificial intelligence to support earlier detection of neonatal seizures. The device is designed to make clinical-grade brain monitoring more accessible, particularly in hospitals where specialist neurophysiology expertise may not always be available.

The latest investment will support NeuroBell as it prepares for US Food and Drug Administration (FDA) clearance and expands its commercial activities in the United States. Parkview Health's participation in the funding round also strengthens an existing clinical partnership and provides an important route into the US healthcare market.

Speaking about the funding, Dr Mark O'Sullivan, CEO and co-founder of NeuroBell, said: "LUNA exists to put clinical-grade brain monitoring in the hands of every NICU team, wherever they are. This investment gives us the resources to scale that vision to patients in the US and across Europe."

NeuroBell spun out from UCC in January 2024 following a €2.1 million investment round. Since then, the company has continued to advance the development of its technology, building on almost a decade of research into newborn brain health and progressing towards commercialisation.